Global Persistent Corneal Epithelial Defect (PCED) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035

Global Persistent Corneal Epithelial Defect (PCED) Market Outlook

Thelansis's "Global Persistent Corneal Epithelial Defect (PCED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Persistent Corneal Epithelial Defect treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Persistent Corneal Epithelial Defect (PCED) Overview

Persistent corneal epithelial defect (PCED) is a severe ocular pathology defined by the failure of the corneal epithelium to close within two weeks despite standard management. Resulting from a disrupted regenerative cycle, it stems from neurotrophic keratopathy, limbal stem cell deficiency, chemical burns, or severe ocular surface disease. Left untreated, chronic defects risk stromal melting, perforation, and permanent scarring. Diagnosis relies on slit-lamp biomicroscopy with fluorescein staining, corneal sensitivity tracking, and anterior segment OCT. Foundational management utilizes preservative-free lubrication, therapeutic bandage contact lenses, and low-dose oral doxycycline to inhibit tissue-degrading matrix metalloproteinases. Biologic repair utilizes autologous or allogeneic serum drops, while the recombinant nerve growth factor cenegermin serves as the approved frontline standard specifically for neurotrophic defects. In 2026, non-neurotrophic pathways target mechanical and cellular restoration via pipeline options like lufepirsen ophthalmic gel or secretome drops. Amniotic membrane transplantation or tarsorrhaphy is reserved for refractory cases requiring aggressive closure.

Key Highlights

• In Germany, relapse and refractory Persistent Corneal Epithelial Defect (PCED) cases are projected to increase from 718 patients in 2025 to 827 patients by 2035, reflecting a gradual rise in disease burden.
• Persistent Corneal Epithelial Defect remains a serious ocular surface condition associated with impaired corneal healing, vision loss risk, and recurrent disease progression.
• Increasing awareness, improved ophthalmic diagnostics, and rising prevalence of underlying conditions such as neurotrophic keratitis and diabetes are contributing to higher diagnosis rates.
• Significant unmet need persists in relapse and refractory patients who demonstrate inadequate response to conventional lubricants, bandage contact lenses, and supportive therapies.
• Growing focus on biologics, regenerative therapies, and novel ophthalmic formulations is expected to transform the treatment landscape over the forecast period.
• The global neurotrophic keratitis treatment market is projected to grow at nearly 9% CAGR through 2030, supported by increasing biologic adoption and expanding recognition of rare corneal disorders.

Market Overview

• The Germany Persistent Corneal Epithelial Defect market is projected to grow from USD 23.84 million in 2025 to USD 212.89 million by 2035, indicating strong market expansion.
• Market growth is driven by:
• Increasing diagnosis of refractory and relapse cases
• Rising adoption of advanced biologics and regenerative ophthalmic therapies
• Improved access to specialty eye care and rare disease management
• Market value is supported by premium pricing of innovative therapies and growing demand for treatments capable of accelerating corneal healing and preventing recurrence.
• Emerging therapies targeting corneal regeneration, nerve healing, and epithelial repair are expected to create substantial commercial opportunities in Germany.
• Future growth will depend on the successful adoption of advanced biologics and therapies capable of improving long-term visual outcomes while reducing recurrence rates.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Dompe Farmaceutici S.p.A.
• Glaukos Corporation